Compare AMS & VTGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AMS | VTGN |
|---|---|---|
| Founded | 1980 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.0M | 9.5M |
| IPO Year | 1995 | 2014 |
| Metric | AMS | VTGN |
|---|---|---|
| Price | $1.26 | $0.19 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $1.00 |
| AVG Volume (30 Days) | 8.8K | ★ 18.0M |
| Earning Date | 11-12-2026 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $19,714,000.00 | N/A |
| Revenue This Year | $16.37 | $33.96 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 0.81 | N/A |
| 52 Week Low | $1.21 | $0.19 |
| 52 Week High | $2.39 | $5.14 |
| Indicator | AMS | VTGN |
|---|---|---|
| Relative Strength Index (RSI) | 29.71 | 33.60 |
| Support Level | N/A | N/A |
| Resistance Level | $1.52 | $0.32 |
| Average True Range (ATR) | 0.05 | 0.02 |
| MACD | -0.01 | -0.01 |
| Stochastic Oscillator | 16.32 | 4.96 |
American Shared Hospital Services provides stereotactic radiosurgery equipment, Advanced radiation therapy, and related equipment. It currently provides Gamma Knife units to medical centers and stand-alone facilities. Company operates in two segments, the medical equipment leasing segment where a contract exists between the hospital and the Company and the direct patient services segment, where a contract exists between the Company facilities and the individual treated at the facility. The company, along with its subsidiaries, operates through the following operations: Gamma Knife, Advanced Radiation Therapy Equipment and Services, and Proton Beam Radiation Therapy Operations. It generates it's key revenue from the domestic market.
Vistagen Therapeutics Inc is a late clinical-stage therapeutics company focused on developing and commercializing medicines for patients with social anxiety disorder, depression, menopausal hot flashes, psychomotor impairment due to mental fatigue, and cancer cachexia. The company is engaged in developing intranasal product candidates called pherines, which leverage the understanding of nose-to-brain neurocircuitry. Vistagen's pherine pipeline consists of various product candidates like: Fasedienol, Itruvone, PH15, Refisolone, and PH284, which are being developed to provide treatment for a variety of disorders. Additionally, it is seeking potential partners for the further clinical development and commercialization of an oral drug candidate, AV-101, to treat certain neurological disorders.